Kathy S. Albain

42.8k total citations · 8 hit papers
234 papers, 19.1k citations indexed

About

Kathy S. Albain is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kathy S. Albain has authored 234 papers receiving a total of 19.1k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Oncology, 101 papers in Pulmonary and Respiratory Medicine and 76 papers in Cancer Research. Recurrent topics in Kathy S. Albain's work include Lung Cancer Treatments and Mutations (66 papers), Breast Cancer Treatment Studies (63 papers) and Cancer Treatment and Pharmacology (47 papers). Kathy S. Albain is often cited by papers focused on Lung Cancer Treatments and Mutations (66 papers), Breast Cancer Treatment Studies (63 papers) and Cancer Treatment and Pharmacology (47 papers). Kathy S. Albain collaborates with scholars based in United States, Canada and France. Kathy S. Albain's co-authors include John J. Crowley, Robert B. Livingston, Joseph M. Unger, Charles A. Coltman, Laura F. Hutchins, David R. Gandara, Michael LeBlanc, Karen Kelly, Valerie W. Rusch and Andrew T. Turrisi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Kathy S. Albain

229 papers receiving 18.5k citations

Hit Papers

Efficacy of Gefitinib, an Inhibitor of the Epider... 1986 2026 1999 2012 2003 1999 2009 2003 1995 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
    2003 2.1k citations Karen Kelly, Kathy S. Albain et al. profile →
  2. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
    1999 1.7k citations Joseph M. Unger, John J. Crowley et al. profile →
  3. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    2009 999 citations Kathy S. Albain, Frances A. Shepherd et al. profile →
  4. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
    2003 737 citations James N. Ingle, Julie R. Gralow et al. Journal of Clinical Oncology profile →
  5. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    1995 633 citations Kathy S. Albain, John J. Crowley et al. Journal of Clinical Oncology profile →
  6. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
    1991 607 citations Kathy S. Albain, John J. Crowley et al. Journal of Clinical Oncology profile →
  7. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
    1986 567 citations Kathy S. Albain et al. Journal of Clinical Oncology profile →
  8. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    2015 458 citations Kathy S. Albain, Hope S. Rugo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathy S. Albain United States 61 11.9k 9.2k 3.8k 2.9k 2.1k 234 19.1k
Susan Halabi United States 61 6.6k 0.6× 10.0k 1.1× 4.8k 1.3× 3.9k 1.3× 2.5k 1.2× 386 16.9k
Nadia Howlader United States 28 8.5k 0.7× 4.5k 0.5× 3.2k 0.8× 3.1k 1.0× 1.1k 0.5× 52 17.4k
Tomasz M. Beer United States 59 6.1k 0.5× 10.8k 1.2× 4.3k 1.1× 4.3k 1.5× 3.6k 1.7× 406 18.0k
Primo N. Lara United States 60 7.0k 0.6× 8.5k 0.9× 3.5k 0.9× 6.0k 2.1× 1.5k 0.7× 458 16.3k
Richard L. Schilsky United States 75 13.8k 1.2× 6.0k 0.7× 5.3k 1.4× 4.8k 1.6× 1.5k 0.7× 382 23.2k
David H. Johnson United States 51 14.3k 1.2× 9.3k 1.0× 1.8k 0.5× 4.9k 1.7× 1.0k 0.5× 241 20.2k
Sabino De Placido Italy 64 7.8k 0.7× 4.5k 0.5× 3.7k 1.0× 4.4k 1.5× 1.6k 0.8× 381 14.0k
Michaele C. Christian United States 28 9.4k 0.8× 6.9k 0.8× 2.7k 0.7× 3.6k 1.2× 2.5k 1.2× 48 18.5k
Sjoerd Rodenhuis Netherlands 60 6.0k 0.5× 4.3k 0.5× 3.4k 0.9× 3.6k 1.2× 1.2k 0.6× 253 12.8k
Eitan Amir Canada 57 8.8k 0.7× 3.9k 0.4× 3.6k 0.9× 2.6k 0.9× 1.5k 0.7× 416 15.4k

Countries citing papers authored by Kathy S. Albain

Since Specialization
Citations

This map shows the geographic impact of Kathy S. Albain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy S. Albain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy S. Albain more than expected).

Fields of papers citing papers by Kathy S. Albain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy S. Albain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy S. Albain. The network helps show where Kathy S. Albain may publish in the future.

Co-authorship network of co-authors of Kathy S. Albain

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy S. Albain. A scholar is included among the top collaborators of Kathy S. Albain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy S. Albain. Kathy S. Albain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bardia, Aditya, Lajos Pusztai, Kathy S. Albain, et al.. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology. 16. 12693072–12693072. 16 indexed citations
3.
Shatsky, Rebecca, Meghna S. Trivedi, Coral Omene, et al.. (2024). Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA501–LBA501. 10 indexed citations
4.
Zirpoli, Gary, William E. Barlow, G. Thomas Budd, et al.. (2023). Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. 21(11). 1172–1180.e3. 15 indexed citations
5.
Cannioto, Rikki, Kristopher Attwood, Alan D. Hutson, et al.. (2023). Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Network Open. 6(5). e2311673–e2311673. 17 indexed citations
6.
Jusué-Torres, Ignacio, Alicia Hulbert, Kathy S. Albain, et al.. (2021). Socioeconomic Disparities in Non-Small Cell Lung Cancer With Brain Metastases at Presentation: A Population-Based Study. World Neurosurgery. 154. e236–e244. 1 indexed citations
7.
Woodward, Wendy A., William E. Barlow, Reshma Jagsi, et al.. (2020). Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology. 6(4). 505–505. 50 indexed citations
8.
Peiffer, Daniel S., Debra Wyatt, Andrei Zlobin, et al.. (2019). DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor–Positive Breast Cancer Following Endocrine Therapy. Cancer Research. 79(19). 4965–4977. 32 indexed citations
9.
Fehrenbacher, Louis, Reena S. Cecchini, Charles E. Geyer, et al.. (2019). NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. Journal of Clinical Oncology. 38(5). 444–453. 279 indexed citations
10.
Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations
11.
Phillips, Gail D. Lewis, Carter T. Fields, Guangmin Li, et al.. (2013). Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy. Clinical Cancer Research. 20(2). 456–468. 148 indexed citations
12.
Hershman, Dawn L., Joseph M. Unger, Katherine D. Crew, et al.. (2013). Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Journal of Clinical Oncology. 31(20). 2627–2633. 145 indexed citations
13.
Livingston, Robert B., William E. Barlow, Joseph J. Kash, et al.. (2011). SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Research and Treatment. 130(1). 123–131. 4 indexed citations
14.
Selever, Jennifer, Guowei Gu, Michael T. Lewis, et al.. (2011). Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells. Clinical Cancer Research. 17(20). 6510–6521. 45 indexed citations
15.
Tubbs, Raymond, William E. Barlow, G. Thomas Budd, et al.. (2009). Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status. Journal of Clinical Oncology. 27(24). 3881–3886. 53 indexed citations
16.
Davies, Angela M., Kari Chansky, Primo N. Lara, et al.. (2009). Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339). Journal of Thoracic Oncology. 4(1). 87–92. 64 indexed citations
17.
Kelly, Karen, Kari Chansky, Laurie E. Gaspar, et al.. (2008). Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology. 26(15). 2450–2456. 421 indexed citations
18.
Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations
19.
Goodwin, J. Wendall, Jeffrey K. Giguere, Karen L. Hoelzer, et al.. (2001). Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626. Breast Cancer Research and Treatment. 69(3). 2 indexed citations
20.
Albain, Kathy S., et al.. (1993). Age less than 35 is associated with high percent S-phase, abnormal P53, and adverse breast cancer outcome. Breast Cancer Research and Treatment. 27. 131. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Halabi Breakdown of academic impact, for papers by Nadia Howlader Breakdown of academic impact, for papers by Tomasz M. Beer Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by Richard L. Schilsky Breakdown of academic impact, for papers by David H. Johnson Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Michaele C. Christian Breakdown of academic impact, for papers by Sjoerd Rodenhuis Breakdown of academic impact, for papers by Eitan Amir
Rankless by CCL
2026